17 September 2020  
EMA/477904/2020  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Kalydeco 
ivacaftor 
On 17 September 2020, the Committee for Medicinal Products for Human Use (CHMP) adopted a 
positive opinion recommending a change to the terms of the marketing authorisation for the medicinal 
product Kalydeco. The marketing authorisation holder for this medicinal product is Vertex 
Pharmaceuticals (Ireland) Limited. 
The CHMP adopted an extension to the existing indication as follows:2  
Kalydeco granules are indicated for the treatment of infants aged at least 6 months 4 months, 
toddlers and children weighing 5 kg to less than 25 kg with cystic fibrosis (CF) who have an 
R117H CFTR mutation or one of the following gating (class III) mutations in the CFTR gene: 
G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R (see sections 4.4 
and 5.1). 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment 
report (EPAR), and will be available in all official European Union languages after a decision on this 
change to the marketing authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 New text in bold, removed text as strikethrough 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. 
 
  
 
 
 
  
 
 
